Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis

BACKGROUND: Vandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as...

Descripción completa

Detalles Bibliográficos
Autores principales: Trimboli, Pierpaolo, Castellana, Marco, Virili, Camilla, Giorgino, Francesco, Giovanella, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943569/
https://www.ncbi.nlm.nih.gov/pubmed/29774010
http://dx.doi.org/10.3389/fendo.2018.00224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943569/
https://www.ncbi.nlm.nih.gov/pubmed/29774010
http://dx.doi.org/10.3389/fendo.2018.00224

Ejemplares similares